Clinical Topics & News

Hashimoto’s Thyroiditis and Lymphoma

From a recent case study, researchers find best practices for diagnosing and treating patients with Hashimoto’s thyroiditis.


 

A “heightened index of suspicion” is called for when a patient with Hashimoto’s thyroiditis (HT) presents with an enlarging neck mass, say researchers from Tan Tock Seng Hospital, Singapore, in a case report. According to the researchers, because the complication of thyroid lymphoma is rare, physicians commonly forgotten it. But primary thyroid lymphomas (PTLs) have a 60-fold risk in patients with HT.

Related: Study Points to Risk Factors for Lymphoma

Hashimoto’s thyroiditis typically is treated successfully with thyroxine. The study patient, however, began to lose weight and developed a mass in her neck that was diagnosed as diffuse large B-cell lymphoma. Previously, research suggested that having HT for ≥ 20 years increased the risk of thyroid lymphoma, but small studies have found that the interval between diagnosis of HT and diagnosis of thyroid lymphoma might be shorter—4 to 9 years, the researchers note. They cite another study that found the median interval was 18 months, as with their patient. Symptoms usually last from a few days to 36 months before diagnosis; in the study patient, symptoms of compression occurred over 2 to 3 weeks.

That shorter time frame may indicate that ultrasonography surveillance should be started early and done periodically, the researchers say, to detect lymphoma development as soon as possible. Radiologic imaging is helpful but “only serves as an adjunct to the diagnosis.” Histologic diagnosis is still needed for definitive diagnosis.

Related: Use of Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of Intravascular Diffuse Large B-Cell Lymphoma

Timely diagnosis and early treatment mean the prognosis can be good for PTL, with relatively high survival rates after chemotherapy and radiotherapy. In this case, the patient underwent 6 cycles of chemotherapy with adjuvant radiotherapy. She then was maintained on thyroxine 75 µg daily. She remains euthyroid and disease free 1 year after completing her cancer treatment.

Source:
Chiang B, Cheng S, Seow CJ. BMJ Case Rep. 2016;pii:bcr2016217568.
doi: 10.1136/bcr-2016-217568.

Recommended Reading

Can Serum Free Light Chains Be Used for the Early Diagnosis of Monoclonal Immunoglobulin-Secreting B-Cell and Plasma-Cell Diseases? (FULL)
AVAHO
Daratumumab Effective in Combo Regimen
AVAHO
Pneumatic Tube-Induced Reverse Pseudohyperkalemia in a Patient With Chronic Lymphocytic Leukemia
AVAHO
Implementing a New Protocol for Heparin Anticoagulation
AVAHO
Influence of Tyrosine Kinase Inhibitors on Renal Function and Current Monitoring Procedures at the Cincinnati Veterans Affairs Medical Center
AVAHO
Demographic and Clinical Characteristics of Patients With Polycythemia Vera (PV) in the U.S. Veterans Population
AVAHO
Double-Expressor Lymphoma (DEL) in Veterans at DC VAMC
AVAHO
CT-Guided Bone Marrow Aspiration and Biopsy Is a Safe and Feasible Option to Decompress Busy Hematology/Oncology Clinics
AVAHO
Managing MGUS Consultations Electronically—A Single Center Experience
AVAHO
Study Points to Risk Factors for Lymphoma
AVAHO

Related Articles